Global health giant Medtronic is further diversifying. Once known primarily for pacemakers, the company has grown over the years to become a leader in spinal and muscoloskeletal therapies and neurostimulation systems, among other things. As of 2017, Medtronic was the largest medical device company in the world by revenue. In November 2018, the company acquired Nutrino, an AI powered personalized nutrition platform, with plans to roll it into Medtronic's diabetes management unit. That has now been taken one step further.
Medtronic recently applied for its own first patent in the nutrition space of the AI biotech sector, and it is not just related to diabetes. The patent involves creating a personal nutritional schedule for each user in order to live a healthier lifestyle. While this does have strong implications in diabetes management, it may point towards Medtronic expanding outside of traditional healthcare and into the larger consumer market.
